We would love to hear your thoughts about our site and services, please take our survey here.
TB - 23.23%
KS - 5.23%
FAB - 3.68%
(from IQAI website - figures from 19/1)
In past years, TB & FAB have had much bigger slice of the company. We have all discussed this magical "30%" mark that TB stays just under ... he is now way under that (I believe that FAB is now in his son's name?). Historically, TB has been quite fastidious in keeping The Browns close but not touching the 30%.
Could it be that for a shark to swallow the minnow there needs to be less "family ownership"?
Could it be that TB is actually "encouraging" P.I.s to get involved before an offer comes in from an external party?
I note that KS still has her 5% and MS must have a small slice too (no selling there).
If this company was going to the wall, KS & MS would be selling too ... (KS slice worth around £300k).
Just a few thoughts ...
-- BB --
This link may help - https://screenrec.com/share/h3IL0wNVY1
note that it is virtually up to date (19.01.2024)
-- BB --
Jimzi,
The scientists/co-founders at Imaging Biometrics - Kathleen and Michael Schmainda - have a sizeable chunk of IQAI stock ...
-- BB --
I am not the biggest fan of "how" this company is run BUT if TB wanted to go private, he would have done so a while ago ... he can't just say "I am going private" and its fait accomplit. He must also know that the voucher-news is imminent ... any day ... so to go private after the news (hopefully positive!) would be crazy.
Also, other "major" sharholders are US-based and that has its own implications.
We go through this every January.... and yes, it is unsettling if you are a trader ... but for the LTHs (like myself), this is just part & parcel of the investment churn. Stay positive and keep buying in the dips. In the end, when this company goes private/bought/sold etc etc, the more stock you have (at this price), the better!
-- BB--
Would be a delight if its Bayer ... or even one of our US friends - Michael, Katherine etc ... but at this stage, anyone or company that is associated with pharma/biotech would be great for SP and shareholder sentiment ...
-- BB --
Jan 21st 2022 - 6.25 (year high 6.75 to low 1.65)
Jan 21st 2023 - 3 (year high 5.8 to low 1.8)
Jan 21st 2024 - 3 (year high 5.05 to 3 the moment ... )
Have we REALLY lost 40% of the SP in juts a few days???
It's all rather disappointing for the majority .... although it seems the minority is benefiting ...
-- BB --
X (Twit)
-- BB --
Https://t.co/WSG12zpR4g
-- BB --
Tyke,
Yes ... it is rather intriguing.
The USA is key to the future of IQ-AI and that's where the focus is.
The Team out there is doing the stirling work and TB is watching and commenting from afar. I think this maybe a good thing.
I note that BRH (Braveheart) is whimpering along too with the same shareholder "complaints" of how they are being treated. Its highs of 128.5p in 2021 to 9p today must be of great stress for its LTHs.
We are in a situation now that for first-timers, this is a GREAT buy-in price ... but for us LTHs, this is just another (and sadly once-too-often) period of negativity ...
Still - we must remember that a) volume is low so the pendulum swings deeply both ways b) we have received periodic good news (FDA etc) which in most companies would see a huge & sustained SP rise ... we can only hope our time comes sooner rather than later ..
-- BB --
Gosh, I know how you feel ... BUT I am not sure he is just "going to walk" as there are too many stakeholders involved and indeed he has worked quite hard to get this far.
I did email TB late last year asking whether he would be conducting any interviews and he stated "I have no plans to be interviewed, but I do have plans to let shareholders judge the company by its performance over the next couple of years" ...
So let's see whether he is a man of his words ...
-- BB --
Https://t.co/MP9JLKorNY
-- BB --
Https://mailchi.mp/imagingbiometrics/optimization-of-surgical-targets-in-neurosurgery-17642043
A great read ...
-- BB --
Imaging Biometrics, LLC (IB), a wholly owned subsidiary of IQ-AI Ltd (LSE: IQAI, OTCBB: IQAIF), is launching an intermediate population cohort expanded access program (EAP) for oral gallium maltolate (GaM), subject to FDA approval. The EAP will be for brain tumor patients located throughout the United States who are unable to participate in the phase 1 clinical trial on-going at the Medical College of Wiscsonsin (MCW). The FDA's recent Fast Track Designation for GaM serves as the motivation behind this launch.
** subject to FDA approval **
-- BB --
Hells-bells ...
Every time we see a bit of blue ... whoosh, the SP gets kicked in the goolies by FAB sells ...
Thankfully, my skin is as "thick as an IQAI investor" -- thicker than that of a rhino!
A positive RNS or two would be very welcomed.
-- BB --
Https://photos.app.goo.gl/myunHcdfj2jv7HQW9
https://photos.app.goo.gl/RReVScVum68SRot8A
Interesting read
--BB--
Sorry if this has already been posted BUT this was from Michael's LinkedIn from a week ago ...
https://screenrec.com/share/2Fwb6eZxC5
-- BB --
Https://www.froedtert.com/stories/app-offers-faster-response-when-cancer-spreads-brain
-- BB --
As long as we don't have to rely on TB to bail us out financially any more .. that will help the sentiment of investors ... and indeed the SP.
-- BB --
TB's CLN clearance is an annual event ... so it's been on the cards.
We must remember that when the Company needed cash, he stumped it up.
Hopefully we are now "self-generating" and no need for more CLNs ... so this is hopefully the last year we go through this!
-- BB --
Dec 19, 2023 - Imaging Biometrics, LLC (IB), a wholly owned subsidiary of IQ-AI Ltd (LSE: IQAI), is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted "Fast-Track" designation for oral gallium maltolate (GaM), IB's therapeutic for the treatment of adult patients with relapsed or refractory glioblastoma (GBM), IDH-wildtype.
The FDA's decision to grant Fast-Track status reflects the urgency and unmet medical need associated with GBM. Receiving both Fast-Track and Orphan Drug designations from the FDA for oral GaM validates the importance of advancing the development of this treatment for these patients.
Fast-Track designation offers an accelerated review process with the FDA via increased communication and collaboration during the development process. IB is now well positioned to utilize this streamlined and efficient process to bring this promising agent to the market as quickly as possible.
"We are very pleased to receive Fast Track designation," said Trevor Brown, CEO of IQ-AI. "This is an important milestone as well as a commercial accelerator, and we are firmly committed to working closely with the FDA to expedite the clinical development of oral GaM."